Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma, T-Cell, Cutaneous 4Leukemia-Lymphoma, Adult T-Cell 4Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3Carcinoma 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Hematologic Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × mogamulizumab × Clear all
NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
38 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡